Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Dementia with Lewy bodies

Lookup NU author(s): Professor Ian McKeith

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Dementia with Lewy bodies (DLB) is the second most common cause of neurogenerative dementia in elderly people, accounting for 10–15% of all cases of dementia. It occupies part of a spectrum of disorders that includes Parkinson’s disease and primary autonomic failure, all of which share a neuritic pathology based on abnormal aggregation of the normally occurring synaptic protein α-synuclein. It is important to identify DLB patients accurately because they have specific symptoms, impairments and functional disabilities that differ from other common dementia syndromes, including Alzheimer’s disease, vascular cognitive impairment and fronto-temporal dementia. Recently revised clinical diagnostic criteria for DLB have been refined in an attempt to identify a substantial minority of cases with atypical presentations that are often due to the presence of mixed pathology. Newly developed rating scales for the core features of DLB (fluctuation, visual hallucinations and Parkinsonism) promise to improve clinical diagnostic accuracy, as does the use of structural and functional neuroimaging, particularly of dopamine transporter activity in the basal ganglia. DLB patients frequently have severe neuroleptic sensitivity reactions, which are associated with significantly increased morbidity and mortality. Cholinesterase inhibitor treatment is usually well tolerated and substantially improves cognitive and neuropsychiatric symptoms. Virtually unrecognized 20 years ago, DLB may, within this decade, be one of the most treatable neurodegenerative disorders of late life.


Publication metadata

Author(s): McKeith I

Publication type: Article

Publication status: Published

Journal: Psychiatry

Year: 2007

Volume: 7

Issue: 1

Pages: 20-23

ISSN (print): 0838-7982

Publisher: MPI Medical Publishing Inc.

URL: http://dx.doi.org/10.1016/j.mppsy.2007.11.010

DOI: 10.1016/j.mppsy.2007.11.010


Altmetrics

Altmetrics provided by Altmetric


Share